SecBot SecBot
6-K ·Filed May 18, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizondays Processed6mo ago SEC0001575872-26-000341
Notable filing: 6-K
Actionable Insight • Neutral

This filing is a procedural submission of an earnings transcript. As no new data is provided, there is no immediate actionable signal. Monitor the transcript content for any guidance changes or material updates that could affect the stock.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.60
T+0 close · May 18, 2026 · via day close
Latest settled
−8.90%
T+60 · $12.39
Vs SPY
−13.75%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $13.60entry
  2. T+1 · 6mo ago −1.10%α −0.45% · $13.45
  3. T+5 · 6mo ago +1.10%α −0.52% · $13.75
  4. T+20 · 5mo ago −2.21%α −3.79% · $13.30
  5. T+60 · 3mo ago −8.90%α −13.75% · $12.39
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's submitted a 6-K filing enclosing the transcript of its Q4 FY2026 earnings call held on May 12, 2026. The filing itself contains no new financial data or material disclosures, it is a routine procedural submission of the call transcript. Traders should review the transcript for any material updates, but this filing alone has no immediate stock impact.

Key Facts

  • Form 6-K filed on May 18, 2026, covering the period ended May 18, 2026.
  • Exhibit 99.1 is a letter to stock exchanges enclosing the earnings call transcript for Q4 FY2026.
  • No financial figures or material business updates are provided in the filing itself.
  • The transcript is available via a weblink included in the exhibit.

Financial Impact

No financial data disclosed in this filing.

Risk Factors

  • The transcript may contain adverse or unexpected commentary not reflected in this filing.
  • Absence of financial details in the filing itself limits visibility into results.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
50% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000341
Document: 0001575872-26-000341-index.html0001575872-26-000341
Document: 0001575872-26-000341.txt0001575872-26-000341

Track record

73 reports on RDY

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026